Phase III IMpower130 Study Showed Genentechs TECENTRIQ Atezolizumab Plus Chemotherapy Carboplatin and ABRAXANE Helped People With Metastatic NonSquamous NonSmall Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone

Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the Phase III IMpower130 study met its coprimary endpoints of overall survival OS and progressionfree survival PFS. The combination of TECENTRIQÂ ate...